Skip to main content
main-content

07-12-2018 | Breast cancer | Video

Achieving pCR after neoadjuvant chemotherapy improves event-free and overall survival

Aditya Bardia explains the importance of research done by him and his colleagues validating pCR as a robust surrogate biomarker for outcomes particularly in women with triple negative and HER2-positive breast cancer (5:26).  

Funding for this video was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

image credits